ArticleScientific reports2015
Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
Peng Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
96 papers cite itlatest 60 shown
this papercites it